microRNAs and Esophageal Cancer - Implications for Pathogenesis and Therapy
Journal:
Current Pharmaceutical Design
Volume:
19
Page:
1211-1226
Author(s):
George C. Mayne, Damian J. Hussey and David I. Watson
Therapeutically Targeting MicroRNAs in Liver Cancer
Journal:
Current Pharmaceutical Design
Volume:
19
Page:
1180-1191
Author(s):
Alexandra Drakaki, Maria Hatziapostolou and Dimitrios Iliopoulos
HtrA Protease Family as Therapeutic Targets
Journal:
Current Pharmaceutical Design
Volume:
19
Page:
977-1009
Author(s):
Joanna Skorko-Glonek, Dorota Zurawa-Janicka, Tomasz Koper, Miroslaw Jarzab, Donata Figaj, Przemyslaw Glaza and Barbara Lipinska
The Proteasome in Health and Disease
Journal:
Current Pharmaceutical Design
Volume:
19
Page:
1010-1028
Author(s):
Elzbieta Jankowska, Julia Stoj, Przemyslaw Karpowicz, Pawel A. Osmulski and Maria Gaczynska
Inhibition of RET Activated Pathways: Novel Strategies for Therapeutic Intervention in Human Cancers
Journal:
Current Pharmaceutical Design
Volume:
19
Page:
864-882
Author(s):
Libero Santarpia and Giulia Bottai
Targeting the Akt-pathway to Improve Radiosensitivity in Glioblastoma
Journal:
Current Pharmaceutical Design
Volume:
19
Page:
951-957
Author(s):
Ravi S. Narayan, Carlos Alexandre Fedrigo, Lukas J.A. Stalpers, Brigitta G. Baumert and Peter Sminia
The Intriguing Interplay Between Therapies Targeting the Epidermal Growth Factor Receptor, the Hypoxic Microenvironment and Hypoxia-inducible Factors
Journal:
Current Pharmaceutical Design
Volume:
19
Page:
907-917
Author(s):
An Wouters, Carolien Boeckx, Jan B. Vermorken, Danielle Van den Weyngaert, Marc Peeters and Filip Lardon
PI3K Pathway Inhibitors: Better Not Left Alone
Journal:
Current Pharmaceutical Design
Volume:
19
Page:
895-906
Author(s):
Ben Markman, Jessica J. Tao and Maurizio Scaltriti
Anti-metastatic Treatment in Colorectal Cancer: Targeting Signaling Pathways
Journal:
Current Pharmaceutical Design
Volume:
19
Page:
841-863
Author(s):
Clara Lemos, Ulrike Sack, Felicitas Schmid, Manisha Juneja and Ulrike Stein
Detection and Therapeutic Implications of c-Met Mutations in Small Cell Lung Cancer and Neuroendocrine Tumors
Journal:
Current Pharmaceutical Design
Volume:
19
Page:
833-840
Author(s):
J. Voortman, T. Harada, R.P. Chang, J.K. Killian, M. Suuriniemi, W.I. Smith, P.S. Meltzer, M. Lucchi, Y. Wang and G. Giaccone